What is the new price of Wegovy for cash-paying patients, and how does it compare to the previous price?

The new price of Wegovy for cash-paying patients is $499 per month, which represents a 23% reduction from the previous price of $650.

How does Eli Lilly's pricing strategy for Zepbound compare to Novo Nordisk's for Wegovy?

Eli Lilly has cut the price of its starter dose of Zepbound to $349, while larger doses are available for $499. In contrast, Novo Nordisk offers all doses of Wegovy at $499.

What prompted these price reductions, and how might they impact the market?

The price reductions were prompted by improved supply conditions following FDA declarations that lifted shortages. This move reflects a broader trend of drug manufacturers adjusting pricing strategies amid escalating competition and potential market saturation.

Who is eligible for the reduced pricing of Wegovy through Novo Nordisk's new pharmacy offering?

The reduced pricing of Wegovy is available to patients without insurance or those with commercial insurance that does not cover obesity medications.

3 sources·Health

Novo Nordisk and Eli Lilly Slash Prices for Obesity Drugs Amid Intensifying Competition

Novo Nordisk reduces Wegovy's price to $499, while Eli Lilly cuts Zepbound's starter dose to $349, both targeting uninsured patients.

100%

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).

Mostly Reliable

The underlying sources are generally reliable but sometimes include opinion, propaganda, or minor inaccuracies.

Leans Right

The underlying sources slightly lean right.

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly lucrative market stiffens.
Novo Nordisk cuts Wegovy prices in half for cash-paying consumers
Fox Business·13d
Mostly Reliable
This source is generally reliable but sometimes includes opinion, propaganda, or minor inaccuracies.
·
Leans Right
This outlet slightly leans right.
The price cuts come as supplies improve.
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Boston Herald·13d
Mostly Reliable
This source is generally reliable but sometimes includes opinion, propaganda, or minor inaccuracies.
·
Leans Right
This outlet slightly leans right.
The move comes just over a week after rival Eli Lilly cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online through its direct-to-consumer website.
Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move
New York Post·13d
Mostly Reliable
This source is generally reliable but sometimes includes opinion, propaganda, or minor inaccuracies.
·
Leans Right
This outlet slightly leans right.

Mar 5th, 2025, 5:09 PM ET

Summary

A summary of the key points of this story verified across multiple sources.

Novo Nordisk has halved the price of Wegovy to $499 for cash-paying patients as competition in the obesity drug market heats up, with Eli Lilly also slashing Zepbound's costs. Both companies aim to improve access for uninsured patients as supplies stabilize following FDA declarations lifting shortages. The changes reflect a broader trend where drug manufacturers are adjusting pricing strategies amid escalating competition and potential market saturation.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.

FAQs

A list of follow-up questions readers often ask about this story.